Centre Hospitalier Universitaire De Lille

At Centre Hospitalier Universitaire De Lille, clinical trials in cardiovascular diseases focus on major conditions such as acute coronary syndrome, acute myocardial infarction, heart failure, and transcatheter aortic valve implantation-related care. These studies are designed to test new treatment strategies and improve patient outcomes after serious heart and vessel events.

• Reducing recurrent cardiovascular events after heart attack
• Improving recovery after ST-segment elevation myocardial infarction
• Evaluating safer approaches for aortic stenosis procedures
• Tracking treatment effects in heart failure due to left ventricular systolic dysfunction

Overall, this area combines prevention, recovery, and treatment optimization for people with high-risk cardiac disease.

The site has a strong focus on respiratory tract diseases and neoplasms, especially non-small cell lung cancer, small cell lung cancer, pulmonary hypertension, and pulmonary arterial hypertension. Research here is aimed at testing new cancer therapies, improving survival, and finding better ways to control chronic lung conditions.

• Testing new treatments for metastatic non-small cell lung cancer
• Evaluating options for small cell lung cancer and pleural mesothelioma
• Studying therapies for pulmonary arterial hypertension
• Assessing care for chronic obstructive pulmonary disease

These trials reflect a broad effort to advance both thoracic oncology and lung disease management through more effective and targeted approaches.

Clinical research in hemic and lymphatic diseases includes studies in hemophilia A and B and lymphatic malformations. The main goal is to improve disease control, monitor joint health, and evaluate new options for people living with inherited bleeding or lymphatic conditions.

• Assessing joint outcomes in hemophilia patients on preventive treatment
• Exploring therapy for PIK3CA mutation-associated lymphatic malformations
• Supporting better long-term management of bleeding disorders

This research area is centered on practical improvements in symptom control, complication prevention, and quality of life.

Work in cell physiological phenomena at the site includes studies of disease mechanisms linked to PIK3CA and c-Met or EGFR alterations. These trials aim to better understand how abnormal cell signaling drives disease and to evaluate more precise treatment options.

• Testing targeted therapy for PIK3CA mutation-related disease
• Evaluating treatment approaches for EGFR exon 20 insertion lung cancer
• Studying c-Met overexpressing non-small cell lung cancer

By focusing on molecular features of disease, this research supports more personalized care for selected cancer and rare disease populations.